Ngā hua rapu - Frattini, Mark G
- E whakaatu ana i te 1 - 20 hua o te 20
-
1
-
2
-
3
-
4
Multiple Mechanisms Contribute to Schizosaccharomyces pombe Origin Recognition Complex-DNA Interactions mā Houchens, Christopher R., Lu, Wenyan, Chuang, Ray-Yuan, Frattini, Mark G., Fuller, Alex, Simancek, Pam, Kelly, Thomas J.
I whakaputaina 2008Text -
5
Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase mā Antczak, Christophe, Shum, David, Bassit, Bhramdeo, Frattini, Mark G., Li, Yueming, de Stanchina, Elisa, Scheinberg, David A., Djaballah, Hakim
I whakaputaina 2011Text -
6
An Arrayed Genome-Scale Lentiviral-Enabled Short Hairpin RNA Screen Identifies Lethal and Rescuer Gene Candidates mā Bhinder, Bhavneet, Antczak, Christophe, Ramirez, Christina N., Shum, David, Liu-Sullivan, Nancy, Radu, Constantin, Frattini, Mark G., Djaballah, Hakim
I whakaputaina 2013Text -
7
Comparison of Luminescence ADP Production Assay and Radiometric Scintillation Proximity Assay for Cdc7 Kinase mā Takagi, Toshimitsu, Shum, David, Parisi, Monika, Santos, Ruth E., Radu, Constantin, Calder, Paul, Rizvi, Zahra, Frattini, Mark G., Djaballah, Hakim
I whakaputaina 2011Text -
8
Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA mā Menolfi, Demis, Jiang, Wenxia, Lee, Brian J., Moiseeva, Tatiana, Shao, Zhengping, Estes, Verna, Frattini, Mark G., Bakkenist, Christopher J., Zha, Shan
I whakaputaina 2018Text -
9
Relative Mitochondrial Priming of Malignant Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML mā Vo, Thanh-Trang, Ryan, Jeremy, Carrasco, Ruben, Neuberg, Donna, Rossi, Derrick J., Stone, Richard, DeAngelo, Daniel J., Frattini, Mark G., Letai, Anthony
I whakaputaina 2012Text -
10
Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors mā Antczak, Christophe, Veach, Darren R., Ramirez, Christina N., Minchenko, Maria A., Shum, David, Calder, Paul A., Frattini, Mark G., Clarkson, Bayard, Djaballah, Hakim
I whakaputaina 2009Text -
11
Micafungin Versus Posaconazole Prophylaxis in Acute Leukemia or Myelodysplastic Syndrome: A Randomized Study mā Epstein, David J., Seo, Susan K., Huang, Yao-Ting, Park, Jay H., Klimek, Virginia M., Berman, Ellin, Tallman, Martin S., Frattini, Mark G., Papanicolaou, Genovefa A.
I whakaputaina 2018Text -
12
Human DDK rescues stalled forks and counteracts checkpoint inhibition at unfired origins to complete DNA replication mā Jones, Mathew J.K., Gelot, Camille, Munk, Stephanie, Koren, Amnon, Kawasoe, Yoshitaka, George, Kelly A., Santos, Ruth E., Olsen, Jesper V., McCarroll, Steven A., Frattini, Mark G., Takahashi, Tatsuro S., Jallepalli, Prasad V.
I whakaputaina 2021Text -
13
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nano-Generator Actinium-225-Lintuzumab mā Rosenblat, Todd L., McDevitt, Michael R., Carrasquillo, Jorge A., Pandit-Taskar, Neeta, Frattini, Mark G., Maslak, Peter G., Park, Jae H., Douer, Dan, Cicic, Dragan, Larson, Steven M., Scheinberg, David A., Jurcic, Joseph G.
I whakaputaina 2022Text -
14
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia mā Maslak, Peter G., Dao, Tao, Krug, Lee M., Chanel, Suzanne, Korontsvit, Tatyana, Zakhaleva, Victoria, Zhang, Ronghua, Wolchok, Jedd D., Yuan, Jianda, Pinilla-Ibarz, Javier, Berman, Ellin, Weiss, Mark, Jurcic, Joseph, Frattini, Mark G., Scheinberg, David A.
I whakaputaina 2010Text -
15
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score ma... mā de Botton, Stéphane, Brandwein, Joseph M., Wei, Andrew H., Pigneux, Arnaud, Quesnel, Bruno, Thomas, Xavier, Legrand, Ollivier, Recher, Christian, Chantepie, Sylvain, Hunault‐Berger, Mathilde, Boissel, Nicolas, Nehme, Salem A., Frattini, Mark G., Tosolini, Alessandra, Marion‐Gallois, Roland, Wang, Jixian J., Cameron, Chris, Siddiqui, Muhaimen, Hutton, Brian, Milkovich, Gary, Stein, Eytan M.
I whakaputaina 2021Text -
16
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure mā Zeidan, Amer M., Knaus, Hanna A., Robinson, Tara M., Towlerton, Andrea M.H., Warren, Edus H., Zeidner, Joshua F., Blackford, Amanda L., Duffield, Amy S., Rizzieri, David, Frattini, Mark G., Levy, Yair M., Schroeder, Mark A., Ferguson, Anna, Sheldon, Katherine E., DeZern, Amy E., Gojo, Ivana, Gore, Steven D., Streicher, Howard, Luznik, Leo, Smith, B. Douglas
I whakaputaina 2018Text -
17
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia mā DiNardo, Courtney D., Stein, Anthony S., Stein, Eytan M., Fathi, Amir T., Frankfurt, Olga, Schuh, Andre C., Döhner, Hartmut, Martinelli, Giovanni, Patel, Prapti A., Raffoux, Emmanuel, Tan, Peter, Zeidan, Amer M., de Botton, Stéphane, Kantarjian, Hagop M., Stone, Richard M., Frattini, Mark G., Lersch, Frederik, Gong, Jing, Gianolio, Diego A., Zhang, Vickie, Franovic, Aleksandra, Fan, Bin, Goldwasser, Meredith, Daigle, Scott, Choe, Sung, Wu, Bin, Winkler, Thomas, Vyas, Paresh
I whakaputaina 2021Text -
18
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study mā Stein, Eytan M., DiNardo, Courtney D., Fathi, Amir T., Mims, Alice S., Pratz, Keith W., Savona, Michael R., Stein, Anthony S., Stone, Richard M., Winer, Eric S., Seet, Christopher S., Döhner, Hartmut, Pollyea, Daniel A., McCloskey, James K., Odenike, Olatoyosi, Löwenberg, Bob, Ossenkoppele, Gert J., Patel, Prapti A., Roshal, Mikhail, Frattini, Mark G., Lersch, Frederik, Franovic, Aleksandra, Nabhan, Salah, Fan, Bin, Choe, Sung, Wang, Hongfang, Wu, Bin, Hua, Lei, Almon, Caroline, Cooper, Michael, Kantarjian, Hagop M., Tallman, Martin S.
I whakaputaina 2021Text -
19
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia mā Leeksma, Alexander C., Taylor, Justin, Wu, Bian, Gardner, Jeffrey R., He, Jie, Nahas, Michelle, Gonen, Mithat, Alemayehu, Wendimagegn G., te Raa, Doreen, Walther, Tatjana, Hüllein, Jennifer, Dietrich, Sascha, Claus, Rainer, de Boer, Fransien, de Heer, Koen, Dubois, Julie, Dampmann, Maria, Dürig, Jan, van Oers, Marinus H. J., Geisler, Christian H., Eldering, Eric, Levine, Ross L., Miller, Vincent, Mughal, Tariq, Lamanna, Nicole, Frattini, Mark G., Heaney, Mark L., Zelenetz, Andrew, Zenz, Thorsten, Abdel-Wahab, Omar, Kater, Arnon P.
I whakaputaina 2018Text -
20
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition mā Harding, James J., Lowery, Maeve A., Shih, Alan H., Schvartzman, Juan M., Hou, Shengqi, Famulare, Christopher, Patel, Minal, Roshal, Mikhail, Do, Richard K., Zehir, Ahmet, You, Daoqi, Selcuklu, S. Duygu, Viale, Agnes, Tallman, Martin S., Hyman, David M., Reznik, Ed, Finley, Lydia W.S., Papaemmanuil, Elli, Tosolini, Alessandra, Frattini, Mark G., MacBeth, Kyle J., Liu, Guowen, Fan, Bin, Choe, Sung, Wu, Bin, Janjigian, Yelena Y., Mellinghoff, Ingo K., Diaz, Luis A., Levine, Ross L., Abou-Alfa, Ghassan K., Stein, Eytan M., Intlekofer, Andrew M.
I whakaputaina 2018Text